Prostate cancer in omics era

Abstract

Recent advances in omics technology have prompted extraordinary attempts to define the molecular changes underlying the onset and progression of a variety of complex human diseases, including cancer. Since the advent of sequencing technology, cancer biology has become increasingly reliant on the generation and integration of data generated at these levels. The availability of multi-omic data has transformed medicine and biology by enabling integrated systems-level approaches. Multivariate signatures are expected to play a role in cancer detection, screening, patient classification, assessment of treatment response, and biomarker identification. This review reports current findings and highlights a number of studies that are both novel and groundbreaking in their application of multi Omics to prostate cancer.

Prostate cancer bioinformatics analysis: emerging genomic profiling techniques

“…The heterogenity nature of the various multi-omics data may result in a biased model. The resulting different molecular characteristics of tumor cells lead to effective screening methods for early cancer detection, patient selection strategies, or treatment response assessment ( 10 ).…”

“…Multi-omics data integration studies rely on integrating data from different omics measurements, which yields to comprehensive analysis of the disease that can extract various types of biomarkers. However, it is an expensive approach and complicated to analyze ( 10 ). Table 1 highlights the strengths and drawbacks for different techniques of studying PCa.…”